| |
|
|
Remission Labs Corp. provides laboratory services to physicians from all spectrums of medicine, with the main focus in the field of oncology. We specialize in the area of chemo-sensitivity and chemo-resistance testing. Our laboratory utilizes numerous advanced techniques in the field of molecular biology and genetics with expertise in micro-array analysis.
Remission Labs provides a revolutionary, non-invasive method of testing a cancer patient's sensitivity to chemo-therapeutic agents, monoclonal antibodies, and 41 biological modifiers.
Due to the fact that all of our processes are tested on the patient's metastases, our pharmacogenomic findings combined with clinical evidence based medicine have given oncologists a new diagnostic tool in cancer treatment.
In the United States chemotherapy is recommended according to guidelines generated by statistical data. According to the FDA, the response rate of a patient that follows these guidelines is approximately 20%. Based on our genetic analysis of the metastases, the clinical response of a patient that followed our indications is over 80%.
Our laboratory heavily invests in the exchange of global knowledge and know-how in the fields of oncology, genetics, immunology, and molecular pathology. Remission Labs and its sister companies are members of various global organizations and federations such as:
 EFB (European Federation of Biotechnology)
DECHEMA (German Society of Biotechnology)
ESGT (European Society of Gene Therapy)
ISCGT (International Society in Cancer Gene Therapy)
ELSO (European Life Science Organization)
ISCO (International Society in Chemo-Sensitivity testing in Oncology)
ESHG (European Society of Human Genetics)
|
|
|
|
